NCT05298410View on ClinicalTrials.gov

The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

September 28, 2022

Study Completion Date

October 27, 2022

Conditions
Hypertension
Interventions
OTHER

Limitless

Participants will be instructed to take Limitless for 30 days.

Trial Locations (1)

N6A5R8

KGK Science Inc., London

Sponsors

Collaborators (1)

KGK Science Inc.
All Listed Sponsors
collaborator

KGK Science Inc.

INDUSTRY

lead

Limitless Research Inc.

OTHER